

Επιλεγμένες Διεθνείς Δημοσιεύσεις

Κώστας Αθανασάκης

Επίκουρος Καθηγητής Οικονομικών της Υγείας και
Αξιολόγησης Τεχνολογιών Υγείας

Τμήμα Πολιτικών Δημόσιας Υγείας,

Σχολή Δημόσιας Υγείας,

Πανεπιστήμιο Δυτικής Αττικής



Publications: Papers

1. Zisis K, Naoum V, Athanasakis K. **"A qualitative comparative analysis of health economic evaluation guidelines for Health Technology Assessment in European countries"**. International Journal of Technology Assessment in Health Care 2020 Dec 10:1-8. doi: 10.1017/S0266462320002081. Online ahead of print.
2. Athanasakis K, Kyriopoulos I, Kyriopoulos J. **"Can We Incorporate Societal Values In Resource Allocation Decisions Among Disease Categories? An Empirical Approach"**. Value in Health Regional Issues, 2020.
3. Athanasakis K, Prodromiadou E, Papazafiropoulou A, Koutsovasilis A, Driva S, Ziori M, Georgopoulos E, Gougourelas D, Sotiropoulos A, Bousboulas S, Melidonis A, Liatis S **"Twenty-year Trends in the Prescription Costs of Type 2 Diabetes: Real World Data and Empirical Analysis in Greece"**. Diabetes Research and Clinical Practice, 2020;162:108095. doi: 10.1016/j.diabres.2020.108095. Epub 2020 Feb 26.
4. Athanasakis K, Pliarchopoulou F, Naoum V, Psarrakis C, Tziolos N, Marantos T, Damoulari C, Chounta A. **"A cost of illness analysis of Hepatocellular Carcinoma for the Greek healthcare setting"** Gastroenterology and Hepatology from Bed to Bench, 2020;13(3):219-222
5. Maltezou H, Dedoukou X, Pavi E, Theodoridou M, Athanasakis K. **"Costs Associated With Measles in Healthcare Personnel During the 2017-2018 Epidemic in Greece: A Real-World Data Cost-Of-Illness Analysis"**. Journal of

Hospital Infections, 2020 May;105(1):91-94. doi: 10.1016/j.jhin.2019.12.006.
Epub 2019 Dec 13.

6. Naoum P, Athanasakis K, Skroumpelos A, Kyriopoulos J. ***“Idiopathic Pulmonary Fibrosis: Utilization of health services and out-of-pocket health expenditure in Greece”***. Value in Health Regional Issues, 2020;22:44-48. doi: 10.1016/j.vhri.2020.04.002.
7. Naoum P, Athanasakis K, Kyriopoulos I, Liapikou A, Toumbis M, Kyriopoulos J. ***“Community acquired pneumonia: a cost-of-illness analysis in Greece”***. Rural Remote Health, 2020 Jun;20(2):5400. doi: 10.22605/RRH5400.
8. Zavras D, Kyriopoulos II, Athanasakis K, Kyriopoulos J. ***“What Influences Self-Perceived Quality of Life During an Economic Recession? The Case of Greece”***. International Journal of Inspiration & Resilience Economy, 2020, 4(2): 41-49 DOI: 10.5923/j.ijire.20200402.01
9. Tsakalogiannis C, Karampli E, Athanasakis K, Kyriopoulos J. ***“The role of Health Technology Assessment in pharmaceutical policy decision-making in Greece. Findings from a qualitative study”***. Journal of Pharmaceutical Health Services Research, 2019, 10; 439–441. <https://doi.org/10.1111/jphs.12319>
10. Petrakis I, Kontogiorgis C, Nena E, Athanasakis K, Gougoula V, Kotsianidis I, Constantinidis T. ***“Unraveling Innovation Potential in the Real-World Setting: Eighteen Novel Agents With Twenty-Six Approved European Indications, in the Management of Leukemias, Lymphomas, and Multiple Myeloma”***. Expert Reviews on Hematology, 2019 Dec;12(12):1063-1075. doi: 10.1080/17474086.2019.1668763.
11. Kostaras D. Karampli E., Athanasakis K. ***“Vaccination against HPV virus: a systematic review of economic evaluation studies for developed countries”***. Expert Review of Pharmacoeconomics & Outcomes Research, 2019; 19 (2): 147-158. doi: [10.1080/14737167.2019.1555039](https://doi.org/10.1080/14737167.2019.1555039)
12. Tentolouris A., Eleutheriadou I., Tzeravini E., Athanasakis K., Anastasiou I., Kyriopoulos J., Tentolouris N. ***“Management of diabetes mellitus and patients’ attitude towards the disease: data from a nationwide study in Greece”***. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2019;13(2):1159-1164. doi.org/10.1016/j.dsx.2019.01.030

13. Gountas I., Sypsa V., Papatheodoridis G., Souliotis K., **Athanasakis K.**, Razzavi H., Hatzakis A. ***"The economic evaluation of the Hepatitis C elimination strategy in Greece in the era of affordable DAAs"***. World Journal of Gastroenterology, 2019; 25(11):1327-1340. doi: 10.3748/wjg.v25.i11.1327
14. Tsironis G., Koutsoukos K., **Athanasakis K.**, Tsiara A., Tzannis K., Gerolympou M., Visvikis A., Oikonomopoulos G., Giannopoulou E., Dimitra M., Kostouros E., Papatsoris A., Dellis A., Stravodimos K., Varkarakis I., Samantas E., Aravantinos G., Kentepozidis N., Christodoulou C., Bozionelou V., Dimopoulos M.A., Bamias A., ***"Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece — the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG)"***. Expert Review of Pharmacoeconomics & Outcomes Research, 2018; 10:1-11. doi: 10.1080/14737167.2019.1546121
15. **Athanasakis K.**, Kyriopoulos I., Kyriopoulos J. ***"To switch or not to switch? Patient attitudes towards generic substitution in Greece"***. Journal of Pharmaceutical Health Services Research (official Journal of the Royal Pharmaceutical Society), 2018; 9: 271-273, doi:[10.1111/jphs.12246](https://doi.org/10.1111/jphs.12246)
16. Kyriopoulos I., **Athanasakis K.**, Kyriopoulos J. ***"Are happy people healthier? An instrumental variable approach using data from Greece"***. Journal of Epidemiology & Community Health, 2018; 72(12): 1153-1161. DOI: 10.1136/jech-2018-210568
17. Tentolouris A., Eleftheriadou I., **Athanasakis K.**, Kyriopoulos J., Tsilimigras D., Grigoropoulou P., Doupis J., Tentolouris N. ***"Prevalence of diabetes mellitus, cardiac and other comorbidities in a representative sample of the adult population of Greece-comparison with the general population"***. Hellenic Journal of Cardiology, 2018; pii: S1109-9666(18)30038-1. doi: 10.1016/j.hjc.2018.04.008. [Epub ahead of print]
18. Orfanos I., Kyriazi K., Orfanou D., Anastasopoulos J., **Athanasakis K.** ***"A pediatric surgery unit: costs and outcomes"***. Journal of Ambulatory Surgery, 2018; 24(4):84-86.
19. The Polaris Observatory collaborators (Razavi-Shearer D., Gamkrelidze I., ... **Athanasakis K.**, ... Khanum S.). ***"Global prevalence, treatment, and prevention of***

- hepatitis B virus infection in 2016: a modelling study*". The Lancet Gastroenterology and Hepatology, 2018;3(6):383-403. doi: 10.1016/S2468-1253(18)30056-6 9
20. Naoum P., Skroumbelos A., Athanasakis K., Kyriopoulos J. "**Factors associated with the utilisation of mammographic screening in Greece**". European Journal of Cancer Prenevtion, 2018;27(1):13-19. doi: 10.1097/CEJ.0000000000000280.
21. Makras P., Boubouchairopoulou N., Katsarolis I., Athanasakis K., "**Cost-effective osteoporosis treatment thresholds for people living with HIV infection in Greece**". Journal of Musculoskeletal and Neuronal Interactions, 2017;17 (4):292-298.
22. Athanasakis K., "**The socioeconomic effects of uncontrolled hypertension**". Current Vascular Pharmacology, 2017;16(1):5-9. doi:10.2174/1570161115666170413145125
23. The European Union HCV Collaborators (Razavi H., Robbins S.... Athanasakis K.,... Weis N., Hatzakis A.). "**Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study**". The Lancet Gastroenterology and Hepatology, 2017;2(5):325-336. doi: 10.1016/S2468-1253(17)30045-6.
24. Athanasakis K., Boubouchairopoulou N., Tarantilis F., Tsiantou V., Kontodimas S., Kyriopoulos J. "**Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece**". Clinical Therapeutics 2017; 39(5): 993-1002. doi: 10.1016/j.clinthera.2017.03.019
25. Kyriopoulos D., Tsiantou V., Papageorgiou L., Theodoropoulou F., Athanasakis K. "**Cost-Minimization and Budget Impact Analysis of Rituximab SC VS Rituximab IV for Non-Hodgkin's Lymphoma (NHLs) in Greece**". Journal of Cancer Therapy 2017;8(08):726-734. doi: 10.4236/jct.2017.88063
26. Athanasakis K., Pliarchopoulou F., Reppas L., Brountzos E., Filippiadis D., Foukas P., Sidiropoulos O., Kyriopoulos J., Boumpas D., Chounta A. "**A cost of illness analysis of Hepatitis B Virus infection in Greece**". Journal of Gastroenterology, Pancreatology and Liver Disorders, 2017;4(5):1-3. doi: 10.15226/2374-815X/4/5/00198

27. Petrakis I., Kyriopoulos I.I., Athanasakis K. ***“Losing a foot versus losing a dollar; a systematic review of cost studies in diabetic foot complications”***. Expert Review of Pharmacoeconomics & Outcomes Research, 2017;17 (2): 165-180. doi: 10.1080/14737167.2017.1305891
28. Charonis A., Kyriopoulos I.I., Spanakis M., Zavras D., Athanasakis K., Pavi E., Kyriopoulos J. ***“Subjective social status, social network and health disparities: empirical evidence from Greece”***. International Journal for Equity in Health, 2017; 27; 16(1): 40. doi: 10.1186/s12939-017-0533-y
29. Balasopoulos T., Charonis A., Athanasakis K., Pavi E., Kyriopoulos I. ***“Why Do Generic Drugs Fail to Achieve an Adequate Market Share in Greece? Empirical Findings and Policy Suggestions”***. Health Policy, 2017; 121 (3): 265-272. doi: 10.1016/j.healthpol.2016.12.011
30. Athanasakis K., Boubouchairopoulou N., Karampli E., Tarantilis F., Savvari P., Bilitou A., Kyriopoulos J. ***“Cost-effectiveness of apixaban versus warfarin or aspirin for stroke prevention in patients with Atrial Fibrillation: a Greek perspective”***. American Journal of Cardiovascular Drugs, 2017; 17(2): 123-133. doi: 10.1007/s40256-016-0204-1.
31. Karachaliou F., Athanasakis K., Tsentidis C., Kitra M., Kyriopoulos J., Karavanaki K. ***“A cohort of children with type 1 diabetes in Greece: predictors of direct costs of care”***. Pediatric Diabetes, 2017; 18(5):405-412. doi: 10.1111/pedi.12408.
32. Kyriopoulos I., Zavras D., Charonis A., Athanasakis K., Pavi E., Kyriopoulos J. ***“Indebtedness, socioeconomic status and self-rated health: empirical evidence from Greece”***. Poverty and Public Policy, 2016; 8(4):387-398. <https://doi.org/10.1002/pop4.160>
33. Tailachidis P., Tsimtsiou Z., Galanis P., Theodorou M., Kouvelas D., Athanasakis K. ***“The Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire: cultural adaptation and validation of the Greek version”***. Hippokratia, 2016;20(4):264-267.
34. Athanasakis K., Arista I., Balasopoulos T., Boubouchairopoulou N., Kyriopoulos J. ***“How peptide technology has improved costs and outcomes in patients with heart failure”***. Expert Review of Pharmacoeconomics & Outcomes Research, 2016; 16 (3): 371-82. doi: 10.1080/14737167.2016.1187066.

35. Athanasakis K., Bilitou A., Lee D., Karampli E., Karavidas A., Parissis J., Sykara G., Kyriopoulos J., ***“Cost-effectiveness of eplerenone in NYHA Class II chronic heart failure patients with reduced LVEF: an analysis for Greece”***. ClinicoEconomics and Outcomes Research, 2016; 8: 583-590.
<https://doi.org/10.2147/CEOR.S107831>
36. Gouvalas A., Igoumenidis M., Theodorou M., Athanasakis K., ***“Cost-sharing rates increase during deep recession: preliminary data from Greece”***. International Journal of Health Policy and Management, 2016; 5 (12): 687-692. doi 10.15171/ijhpm.2016.62
37. Naoum P., Kitsonis D., Topkaroglou I., Skroumpelos A., Athanasakis K., Melexopoulou C., Iatrou C., Boletis J., Kyriopoulos J. ***“ESRD patients in Greece during the financial crisis”***. International Journal of Artificial Organs, 2016;39(5):258–259. doi: 10.5301/ijao.5000495
38. Karampli E., Triga E., Tsiantou V., Athanasakis K., Kyriopoulos J. ***“Views of physicians and patients with chronic conditions on generic medicines in Greece after the introduction of measures to promote their consumption: findings from a qualitative study”***. Generics and Biosimilars Initiative Journal, 2016;(5)1:1-10. doi: 10.5639/gabij.2016.0501.005
39. Boubouchairopoulou N., Flouri I., Drosos A., Boki K., Settas L., Zisopoulos D., Skopouli F., Papadopoulos I., Iliopoulos A., Kyriopoulos J., Boumpas D., Athanasakis K., Sidiropoulos P., ***“Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status”***. Clinical and Experimental Rheumatology, 2016; 34(6): 999-1005
40. Palitzika D., Lavdaniti M., Giapountzi M., Athanasakis K., ***“An investigation of the satisfaction levels of users of the health services in Northern Greece”***. American Journal of Advances in Nursing Research, 2016;3(1):1-5
41. Bertias G., Karampli E., Sidiropoulos P., Drosos A., Sakkas L., Garyfallos A., Tzioufas A., Vassilopoulos D., Sfrikakis P., Athanasakis K., Perna A., Psomali D., Kyriopoulos J., Boumpas D., ***“Clinical and financial burden of active lupus in***

Greece: a nation-wide, multi-centre study". *Lupus*, 2016; 25 (12): 1385-1394.
doi: 10.1177/0961203316642310

42. Naoum P., Topkaroglou I., Kitsonis D., Skroumpelos A., Athanasakis K., Iatrou C., Boletis J., Kyriopoulos J. "**Cost calculations during "dire straits" - A cost of illness analysis of regular haemodialysis for End-Stage Renal Disease in Greece**". *The International Journal of Artificial Organs*, 2016;39(2):87-89. doi: 10.5301/ijao.5000477
43. Oikonomou, N., Tountas, Y., Mariolis, A., Souliotis, K., Athanasakis, K., Kyriopoulos, J., "**Measuring the efficiency of the Greek rural primary health care using a restricted DEA model; the case of southern and western Greece**". *Health Care Management Science*, 2016;19(4):313-325. doi: 10.1007/s10729-015-9324-4
44. Pavlatou N., Koutzoglou M., Papageorgiou D., Panagopoulos G., Igoumenou V., Mavrogenis A., Athanasakis K., "**Self perceived quality of life and absence from work due to health problems of nurses in a Greek Hospital**". *Ethics in Biology, Engineering and Medicine: An International Journal*, 2015;6: 173-185
doi: 10.1615/EthicsBiologyEngMed.2016013645
45. Athanasakis K., Petrakis I., Kyriopoulos J. "**HepConomics: cost-effective indeed. But how can we pay for it?**" *Journal of Viral Hepatitis*, 2015; 22(8): 682. doi: 10.1111/jvh.12396. doi: 10.1111/jvh.12396
46. Athanasakis K., Ferrante S., Kyriopoulos I.I., Petrakis I., Hill M., Retsa M., Kyriopoulos J. "**Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis**". *Clinical Therapeutics*, 2015;37(7):1529-1540. doi: 10.1016/j.clinthera.2015.05.003
47. Makras P., Athanasakis K., Boubouchairopoulou N., Rizou S., Anastasilakis A., Kyriopoulos J., Lyritis G., "**Cost-effective osteoporosis treatment thresholds in Greece**". *Osteoporosis International*, 2015;26(7):1949-1957. doi: 10.1007/s00198-015-3055-8
48. Athanasakis K., Tarantilis F., Tsalapati K., Konstantopoulou T., Kyriopoulos J. "**Cost-utility analysis of Tocilizumab monotherapy in first line versus standard of care for the treatment of Rheumatoid Arthritis in Greece**". *Rheumatology International*, 2015; 35(9): 1489-1495. doi: 10.1007/s00296-015-3253-x

49. Athanasakis K., Karampli E., Tsounis D., Bilitou A., Kyriopoulos J. ***“Cost-effectiveness of apixaban versus other New Oral Anticoagulants for the prevention of stroke: an analysis on patients with Non-Valvular Atrial Fibrillation in the Greek healthcare setting”***. Clinical Drug Investigation, 2015; 35(11):1-13. doi: 10.1007/s40261-015-0321-7.
50. Tsifetaki N., Migkos M., Papagoras C., Voulgari P., Athanasakis K., Drosos A. ***“Counting costs under severe financial constraints: a cost of illness analysis of spondyloarthropaties in Greece”***. Journal of Rheumatology, 2015;42(6):963-967. doi: <https://doi.org/10.3899/jrheum.141277>
51. Parissis J., Athanasakis K., Farmakis D., Boubouchairopoulou N., Mareti C., Bistola V., Ikonomidis I., Kyriopoulos J., Filippatos G., Lekakis J. ***“Determinants of the direct cost of heart failure hospitalization in a public tertiary hospital”***. International Journal of Cardiology, 2015; 180: 46-49. doi: 10.1016/j.ijcard.2014.11.123
52. Tarantilis F., Athanasakis K., Zavras D., Vozikis A., Kyriopoulos J. ***“Estimates of price and income elasticity in Greece: Greek debt crisis transforming cigarettes into a luxury good - an econometric approach”***. BMJ Open, 2015, 5(1):e004748. doi:10.1136/bmjopen-2013-004748
53. Athanasakis K., Kyriopoulos E., Boubouchairopoulou K., Stergiou G. ***“Quantifying the economic benefits of prevention in a healthcare setting with severe financial constraints: the case of hypertension control”***. Clinical and Experimental Hypertension, 2015; 37(5):375-80. doi: 10.3109/10641963.2014.977488.
54. Athanasakis K., Kyriopoulos E., Sideris M., Rentzos M., Evdokimidis I., Kyriopoulos J., ***“Investigating the economic burden of ALS in Greece: a cost-of-illness approach”***. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015; 16(1-2):63-64. doi: 10.3109/21678421.2014.932384
55. Athanasakis K., Petrakis I., Ollandezos M., Tsoulas C., Patel D., Karampli E., Kyriopoulos J., ***“Antibacterial treatment of meticillin-resistant staphylococcus aureus complicated skin and soft tissue infections: A cost and budget impact analysis in the Greek hospital setting”***. Infectious Diseases and Therapy, 2014; 3(2):277-68. doi: [10.1007/s40121-014-0044-8](https://doi.org/10.1007/s40121-014-0044-8)

56. Boubouchairopoulou N., Karpettas N., **Athanasakis K.**, Kollias A., Protogerou A.D., Achimastos A., Stergiou G.S. ***“Cost estimation of hypertension management based on home blood pressure monitoring alone or combined office and ambulatory blood pressure measurements”***. Journal of the American Society of Hypertension, 2014;8(10):732-738. doi: 10.1016/j.jash.2014.07.027
57. Boubouchairopoulou K., **Athanasakis K.**, Chini M., Mangafas N., Lazanas M., Kyriopoulos J. ***“Estimation of the direct cost of HIV-infected patients in Greece on an annual basis”***. Value in Health Regional Issues, 2014;4:82-86. doi:10.1016/j.vhri.2014.07.005
58. Igoumenidis M., **Athanasakis K.** ***“Earmarking Tobacco Taxes for Health Purposes via Median Entities”***. International Journal of Health Policy and Management 2014, 3:159 doi:10.15171/ijhpm.2014.72
59. **Athanasakis K.**, Souliotis K., Tountas Y., Yfantopoulos J., Kyriopoulos J., Hatzakis A. ***“A short-term cost-effectiveness analysis of hypertension treatment in Greece”***. Hellenic Journal of Cardiology, 2014;55(3):197-203.
60. Kyriopoulos I., Zavras D., Skroumpelos A., Mylona K., **Athanasakis K.**, Kyriopoulos J. ***“Barriers in access to healthcare services for chronic patients in times of austerity: an empirical approach in Greece”***. International Journal for Equity in Health, 2014;13:54. doi: 10.1186/1475-9276-13-54
61. Tsalapati K., Vardavas C., **Athanasakis K.**, Thireos E., Vozikis A., Pavi E., Behrakis P., Kyriopoulos I. ***“Going up in ashes? Smoking-attributable morbidity, hospital admissions and expenditure in Greece”***. European Journal of Public Health, 2014;24(3):477-479. doi: 10.1093/eurpub/cku040
62. Karachaliou F., **Athanasakis K.**, Tsentidis C., Kitra M., Kyriopoulos J., Karavanaki K. ***“Direct Costs of Diabetes Care in Pediatric Patients with Type 1 Diabetes in Greece”***. Journal of Diabetes Mellitus, 2014, 4:209-215. doi:10.4236/jdm.2014.43030
63. Alpert H., Vardavas C., Chaloupka F., Vozikis A., **Athanasakis K.**, Kyriopoulos J., Behrakis P., Connolly G., ***“The recent and projected public health economic benefits of cigarette taxation in Greece”***. Tobacco Control, 2014;23(5):452-454. doi: 10.1136/tobaccocontrol-2012-050857

64. Souliotis K., Kartzi G., Athanasakis K, Golna C., Yfantopoulos J., ***“Determinants of Health Care Expenditure in Greece: can primary health care impact on their evolution?”*** International Journal of Pharmaceutical sciences and Research, 2014, 5(2), 383-391
65. Athanasakis K., Petrakis I., Vitsou E., Pimenidou A., Kyriopoulos J., ***“A cost-effectiveness analysis of parecoxib in the management of post-operative pain in the Greek healthcare setting”***. Clinical Therapeutics, 2013;35(8):1118-1124
doi: <https://doi.org/10.1016/j.clinthera.2013.06.004>
66. Athanasakis K., Petrakis I., Karampli E., Vitsou E., Lyras L., Kyriopoulos J. ***“Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: A cost effectiveness analysis for the Greek healthcare setting”***. BMC Neurology, 2013;13(4):56. doi: 10.1186/1471-2377-13-56
67. Athanasakis K., Petrakis I., Kyriopoulos J. ***“Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece”***. Journal of Medical Economics, 2013;16(5):678-84 doi: 10.3111/13696998.2013.781028
68. Igoumenidis M., Kyriopoulos I.I., Athanasakis K., ***“Drug and cash donations to developing countries: problems and proposals”***. Journal of Developing Societies, 2013; 29(3):287–303. doi: <https://doi.org/10.1177/0169796X13494279>
69. Tsoulas C., Petrakis I., Athanasakis K., Vatopoulos A., Vagianos K. ***“The burden of initial empiric antibiotic failure on healthcare resource utilization for hospitalized patients with complicated intra-abdominal infections in Greece”***. Hellenic Journal of Surgery, 2013 85:4, 215-223. doi: <https://doi.org/10.1007/s13126-013-0043-3>
70. Athanasakis K., Petrakis I., Kyriopoulos J. ***“Investigating the value of abatacept in the treatment of rheumatoid arthritis: a systematic review of cost-effectiveness studies”***. ISRN Rheumatology, 2013; Article ID 256871: 15 pages.
doi: <https://doi.org/10.1155/2013/256871>.
71. Kyriopoulos E.J., Athanasakis K., Beazoglou T. ***“State funding for healthcare services and public health: is it based on the principles of economic theory?”*** South-Eastern Europe Journal of Economics , 2013; 1: 37-47

72. Athanasakis K., Igoumenidis M., Karampli E., Vitsou E., Sykara G., Kyriopoulos J., ***“A cost-effectiveness analysis of varenicline versus bupropion, nicotine replacement therapy and unaided cessation in Greece”***. *Clinical Therapeutics*, 2012;34(8):1803-14. doi: 10.1016/j.clinthera.2012.07.002
73. Athanasakis K., Kyriopoulos J., ***“Cost-Effectiveness Analysis of Trastuzumab plus Docetaxel Versus Docetaxel Alone for the Treatment of HER2 - Metastatic Breast Cancer in Greece”***. *Forum of Clinical Oncology*, 2012;3(4):28-34
74. Athanasakis K., Fragoulakis V., Tsiantou V., Masaoutis P., Maniadakis N., Kyriopoulos J., ***“Cost – effectiveness analysis of ranibizumab versus verteporfin, photodynamic therapy, pegaptanib sodium and best supportive care, for the treatment of age-related macular degeneration in Greece”***. *Clinical Therapeutics*, 2012; 34(2):446-456. doi: 10.1016/j.clinthera.2012.01.005
75. Athanasakis K., Detsis M., Baroutsou B., Kyriopoulos J. ***“Clinical Trial activity in Greece: a case of missed opportunities?”*** *Archives of Hellenic Medicine*, 2012;29(6):734-736
76. Karampli E., Athanasakis K., Ollandezos M., Pavi E., Kyriopoulos J., ***“Management of atrial fibrillation in the Greek healthcare setting”***. *Hellenic Journal of Cardiology*, 2012; 53:273-278
77. Athanasakis K., Souliotis K., Kyriopoulos E.J., Loukidou E., Kritikou P., Kyriopoulos J., ***“Inequalities in access to cancer treatment: an analysis of cross-regional patient mobility in Greece”***. *Supportive Care in Cancer*, 2012;20(3):455-460
78. Athanasakis K., Detsis M., Souliotis K., Golna C., Kyriopoulos J. ***“Greek NHS capacity constraints regarding intravenous treatment for rheumatoid arthritis patients”***. *Rheumatology International*, 2012;32(4):921-6. doi: 10.1007/s00296-010-1647-3
79. Athanasakis K., Souliotis K., Tountas Y., Kyriopoulos J., Hatzakis A. ***“A cost-utility analysis of hypertension treatment in Greece; assessing the impact of age, gender and smoking status on outcomes”***. *Journal of Hypertension*, 2012; 30 (1):227-234. doi: 10.1097/HJH.0b013e32834d9f18.
80. Athanasakis K., Igoumenidis M., Kyriopoulos J., ***“Beyond survival: the health economics of trastuzumab”***. *Forum of Clinical Oncology*, 2011; 4(2): 55-61

81. Ollandezos M., Athanasakis K., Lionis C., Kyriopoulos J., Konstantinides T., *"Trends of Mortality in Greece 1980-2007: a focus on avoidable mortality"*. Hippokratia, 2011, 15, 4: 330-334
82. Athanasakis K., Skroubelos A., Tsiantou V., Mylona K., Kyriopoulos J. *"Abolishing Coinsurance for Oral Antihyperglycemics: Effects on Social Insurance Budgets"*. American Journal of Managed Care, 2011;17(2):130-135.
83. Athanasakis K., Konstantinou E., Thireos E., Kyriopoulos J., *"The relative value of medical innovations on population health status: Physicians' views in Greece"*. Archives of Hellenic Medicine, 2010; 27(6):963-969.
84. Athanasakis K., Pavi E., Konstantinides T., Papathanasiou G., Vodenicharov T., Hristov J., Tchamov K., Kyriopoulos J., *"Survey on the curricula of public health training programs across Bulgaria and Greece: opportunities for future collaboration"*. Folia Medica 2010 52 (2) 72-77.
85. Athanasakis K., Ollandezos M., Angeli A., Gregoriou A., Geitona M., Kyriopoulos J., *"Estimating the direct cost of Type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost"*. Diabetic Medicine, 2010; 27: 679–684. doi: 10.1111/j.1464-5491.2010.03004.x.
86. Daniilidou N., Gregory S., Zavras D., Pavi E., Athanasakis K., Lionis C., Kyriopoulos J., *"Comparison between two different measures of self-rated health: a single-question measure and a visual analogue scale"*. Folia Medica, 2010; 52(1):63-69.
87. Daniilidou N., Athanasakis K., Konstantinides T., Papathanasiou G., Hristov J., Kyriopoulos J. *"Critical issues arising from users' assessment of the responsiveness of the Greek health care services"*. Health Policy and Management, 2009; (3): 10-15.
88. Tsiantou V., Athanasakis K., Kyriopoulos J., *"The Greek health care system"*. World Hospitals and Health Services, 2009; 45 (1): 32-34
89. Geitona M., Kousoulakou H., Ollandezos M., Athanasakis K., Zouzoulas E., Papanikolaou S., Kyriopoulos J., *"Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece"*. Annals of General Psychiatry, 2008, 7:16. doi: 10.1186/1744-859X-7-16

90. Geitona M., Ollandezos M., Souliotis K., **Athanasakis K.**, Kyriopoulos J. ***“Cost-minimization analysis of the Oral Anticoagulant Therapy monitoring methods: the case of Prothrombin Time self-monitoring”***. Hellenic Journal of Cardiology 2008; 49: 388-396

Publications: Abstracts

1. **Athanasakis K**, Nomikos N, Souliotis K, Kyriopoulos J. “From Disease Burden to Healthcare Cost: Highlighting the Health Economics Aspects of the COVID-19 Pandemic”. Value in Health, Accepted, Forthcoming, I.F. 5,037
2. Nomikos N, Naoum P, Naoum V, **Athanasakis K**, Kyriopoulos J, Pavi E. “Personal Characteristics Associated with Subscription to Private Health Insurance in Greece – Results from the “Health & Welfare” Survey”. Value in Health, Accepted, Forthcoming, I.F. 5,037
3. Naoum V, Nomikos N, Naoum P, **Athanasakis K**, Kyriopoulos J. “Estimating the Potential Effects of Self-Medication Enhancement in Greece”. Value in Health, Accepted, Forthcoming, I.F. 5,037
4. Naoum P, Nomikos N, **Athanasakis K**, Zavras D, Kyriopoulos J, Pavi E. “Factors Associated with HPV Vaccination of Girls Aged 11-18 years in Greece” Value in Health, Accepted, Forthcoming, I.F. 5,037
5. Ziori M, **Athanasakis K**, Papazafiropoulou A, Koutsovasilis A, Driva S, Prodromiadou E, Sotiropoulos A, Georgopoulos I, Gougourelas D, Melidonis A, Bousboulas S, Liatis S. ***“Prescription cost and patterns of cardiovascular risk management in type 2 diabetes during the last 20 years: a survey in Greek outpatient diabetes centres”***. DIABETOLOGIA 63 (SUPPL 1), S315-S316,
6. **Athanasakis K**, Naoum P, Naoum V, Karampli E, Kyriopoulos J. ***“A multiple criteria decision analysis of darvadstrocel versus standard of care for the treatment of complex perianal fistulas in Crohn's disease”***. Value in Health 2019,
7. **Athanasakis K**, Igoumenidis M, Boubouchairopoulou N, Vitsou E, Kyriopoulos J. ***“Two sides of the same coin? A dual Multiple Criteria Decision Analysis of novel treatments for Rheumatoid Arthritis from physicians' and patients' perspectives in Greece”***. Value in Health, 2019, 22, S907

8. Naoum P, Athanasakis K, Zavras D, Kyriopoulos J. ***“Assessment of risk for development of type 2 diabetes in the Greek population”***. Value in Health, 2019, 22, S585
9. Karampli E, Tsiantou V, Koulierakis G, Naoum V, Naoum P, Athanasakis K, Pavi E, Kyriopoulos J. ***“Healthcare utilisation and perceived health needs of multiple sclerosis patients in Greece: evidence from a qualitative study”***. Value in Health, 2019, 22, S752
10. Naoum V, Naoum P, Tsiantou V, Karampli E, Spiliopoulos P, Ntoumas K, Zavras D, Delakas DS, Theodorou C, Athanasakis K, Kyriopoulos J. ***“Key intervals in the patient journey of men with prostate cancer: evidence from Greece”***. Value in Health, 2019, 22, S499–S500
11. Koulierakis G, Karampli E, Tsiantou V, Naoum V, Naoum P, Athanasakis K, Pavi E, Kyriopoulos J. ***“Patients' perspectives of living with multiple sclerosis in Greece: an interpretive phenomenological analysis”***. Value in Health, 2019, 22, S759
12. Naoum V, Naoum P, Karampli E, Athanasakis K, Kyriopoulos J, Pavi E. ***“Perceptions on the pharmacists' role in HTA decision making in Greece”***. Value in Health, 2019, 22, S805
13. Karampli E, Karabela P, Naoum V, Naoum P, Athanasakis K, Kyriopoulos J. ***“Perspectives on pricing and reimbursement of advanced therapy medicinal products in the Greek healthcare setting: a qualitative study”***. Value in Health, 2019, 22, S808
14. Naoum V, Naoum P, Karampli E, Athanasakis K, Kyriopoulos J, Pavi E. ***“Should the patient voice have an active role in HTA decision-making? A PAG consensus analysis in Greece”***. Value in Health, 2019, 22, S799
15. Zisis K, Naoum P, Athanasakis K, Kyriopoulos J. ***“Systematic review on the economic evaluation of non-invasive prenatal testing”***. Value in Health, 2019, 22, S811
16. Karampli E, Tsiantou V, Maina A, Magoulas C, Naoum V, Naoum P, Bournakis E, Lontos M, Athanasakis K, Samantas E, Kyriopoulos J. ***“The patient journey with metastatic prostate cancer: a pilot qualitative study from Greece”***. Value in Health, 2019, 22, S529

17. Naoum P, Athanasakis K, Kyriopoulos J, Pavi E. ***“What approach should be taken in order to effectively manage behavioral health risk factors? A consensus panel analysis for Greece”***. Value in Health, 2019, 22, S786
18. Karampli E, Athanasakis K, Polyzos N, Souliotis K, Chatzaki E. ***“Adoption of new drugs for type 2 diabetes mellitus: a qualitative study with Greek physicians”***. Value in Health, 2019, 22, S587
19. Athanasakis K, Naoum V, Kyriopoulos J. ***“The development and empirical application of a multiple societal value criteria approach to resource allocation among disease categories”***. Value in Health, 2018, 21, S176
20. Athanasakis K, Kyriopoulos I, Kyriopoulos J. ***“Is it enough to have it in the vaccination programme? An empirical analysis of the factors that affect influenza vaccination uptake in adults in Greece”***. Value in Health, 2018, 21, S207
21. Tsiantou V, Karampli E, Magoulas C, Maina A, Naoum V, Delakas DS, Ntoumas K, Athanasakis K, Theodorou C, Kyriopoulos J. ***“The patient journey of men with localised prostate cancer: results from a qualitative study in Greece”***. Value in Health, 2018, 21, S64
22. Kourkoulas N, Athanasakis K, Kakouros M, Skroumpelos A, Kyriopoulos J. ***“Cost-effectiveness analysis of atezolizumab compared to treatment options for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy: updated results”***. Value in Health, 2018, 21, S39-S40
23. Zavras D, Naoum P, Naoum V, Athanasakis K, Kyriopoulos J, Pavi E. ***“Factors associated with obesity in Greece”***. Value in Health, 2018, 21, S466-S467
24. Kourkoulas N, Athanasakis K, Boubouchairopoulou N, Chouchouli K, Kyriopoulos J. ***“Cost-effectiveness analysis of tofacitinib in combination with methotrexate in the treatment of moderate to severe Rheumatoid Arthritis in Greece”***. Value in Health, 2018, 21, S294
25. Kourkoulas N, Athanasakis K, Kyriopoulos J. ***“Cost effectiveness analysis of alemtuzumab as a treatment option for patients with multiple sclerosis in Greece”***. Value in Health 21, S339, 2018

26. Naoum P, Naoum V, Karampli E, Athanasakis K, Kyriopoulos J. ***“Perceptions of the Greek population concerning medicines—a descriptive analysis”***. Value in Health 2018, 21, S324
27. Zavras D, Naoum P, Athanasakis K, Pavi E, Kyriopoulos J. ***“Socioeconomic determinants of smoking in Greece”***. Value in Health, 2018, 21, S417
28. Kyriakou M, Athanasakis K, Polyzos N, Galanis P, Konstantakopoulou O, Kaitelidou D, Theodorou M. ***“Cost of Motor Neurone Disease in Cyprus”***. Value in Health, 2018, 21, S335
29. Kourkoulas N, Athanasakis K, Theodorou M, Kyriopoulos J. ***“Cost-effectiveness analysis of alemtuzumab as a treatment option for patients with multiple sclerosis in Cyprus”***. Value in Health, 2018, 21, S340
30. Naoum V, Naoum P, Athanasakis K, Pavi E, Kyriopoulos J. ***“Socioeconomic and health-related factors associated with adherence to chronic medication in Greece”***. Value in Health, 2018 21, S321-S322
31. Naoum P, Naoum V, Karampli E, Athanasakis K, Kyriopoulos J. ***“What are the views and perceptions of the Greek population towards the pharmaceutical industry?”***. Value in Health, 2018, 21, S325
32. Naoum P, Kyriopoulos I, Karampli E, Athanasakis K, Kyriopoulos J. ***“Out-of-pocket expenditure for prescribed and over-the-counter medications in Greece”***. Value in Health, 2018, 21, S167
33. Athanasakis K, Kourkoulas N, Boubouchairopoulou N, Kyriopoulos D, Kyriopoulos J. ***“Barriers To Access And Pricing Negotiations Criterial Selection For Novel Treatments For Hepatitis C In The Greek Healthcare Context”***. Value in Health, 2017, 20 (9), A638
34. Pavi E, Athanasakis K, Kyriopoulos J. ***“Positive Externalities of austerity? The Case of Smoking Cessation During the Financial Crisis in Greece”***. Value in Health 20, 2017, (9), A699
35. Braoudaki E, Naoum V, Karampli E, Athanasakis K, Kyriopoulos J. ***“Generics Policies: A Systematic Review Of Their Effectiveness”***. Value in Health, 2017, 20 (9), A662
36. Kyriopoulos D, Athanasakis K, Akrotos A, Theodoropoulou F, Caporis X, Kyriopoulos J. ***“Budget Impact Model of Cobimetinib in Combination with***

- Vemurafenib For Previously Untreated BRAF V600-Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma***". Value in Health, 2017, 20 (9), A423
37. Farmaki A, Balasopoulos T, Theodorou M, Athanasakis K. ***"A Systematic Review of Economic Evaluations of Biological Therapies for the Treatment of Ulcerative Colitis"***". Value in Health, 2017, 20 (9), A635
38. Naoum P, Skroumpelos A, Athanasakis K, Kyriopoulos J. ***"Idiopathic Pulmonary Fibrosis: A Cost Of Illness Analysis In Greece"***". Value in Health 20, 2017, (9), A643
39. Filosofou S, Naoum P, Kyriopoulos D, Athanasakis K, Theodorou M. ***"Time To Market Access For Oncology Medicines In Greece: Has It Changed During The Crisis?"***". Value in Health, 2017, 20 (9), A460
40. Kyriopoulos D, Kyriopoulos I, Athanasakis K. ***"Attitudes Towards Generic Substitution In Greece"***". Value in Health, 2017, 20 (9), A656
41. Naoum P, Liapikou A, Toumbis M, Athanasakis K, Kyriopoulos J ***"A Cost-Of-Illness Analysis For Community Acquired Pneumonia In Greece"***". Value in Health, 2017, 20 (9), A642
42. Skroumpelos A, Naoum P, Athanasakis K, Argyropoulos E, Kyriopoulos J ***"The Economic Impact of Rheumatoid Arthritis on Patients' Households. An Estimation of The Disease Related Catastrophic Health Expenditure in Greece"***". Value in Health, 2017, 20 (9), A543-A544
43. Kourkoulas N, Kyriopoulos D, Athanasakis K. ***"Budget Impact of Atezolizumab for The Treatment of 2nd Line Non-Small Cell Lung Cancer (NSCLC) After Failure with Platinum Containing Chemotherapy in Greece"***". Value in Health, 2017, 20 (9), A423-A424
44. Kourkoulas N, Kyriopoulos D, Athanasakis K. ***"Cost-Effectiveness Analysis of Atezolizumab Compared To The Standard of Care For The Treatment of Adult Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy in Greece"***". Value in Health, 2017, 20 (9), A439
45. Kourkoulas N, Kyriopoulos D, Athanasakis K. ***"Cost-Effectiveness Analysis of Alectinib Compared To Chemotherapy for The Treatment of Treatment-Naïve***

- Patients With ALK Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Greece***". Value in Health, 2017, 20 (9), A433
46. Kourkoulas N, Kyriopoulos D, Athanasakis K. ***"Budget Impact of Alectinib in The Treatment of Naïve Anaplastic Lymphoma Kinase-Positive (ALK+) Advanced Non-Small Cell Lung Cancer (NSCLC) in Greece"***". Value in Health, 2017, 20 (9), A424
47. Zavras D, Naoum P, Athanasakis K, Kyriopoulos J, Pavi E. ***"Unmet Healthcare Needs Due To Financial Reasons In Times Of Austerity"***". Value in Health, 2017, 20 (9), A510-A511
48. Athanasakis K, Tarantilis F, Tsakalogiannis C, Ollandezos M, Kyriopoulos J. ***"A Cost of Illness Analysis of Pulmonary Arterial Hypertension in Greece"***". Value in Health, 2016 19 (7), A647
49. Athanasakis K, Tarantilis F, Tsakalogiannis C, Ollandezos M, Kyriopoulos J. ***"A Budget Impact Analysis of The Introduction of Generic Bosentan For The Treatment of Pulmonary Arterial Hypertension In Greece"***". Value in Health, 2016, 19 (7), A580
50. Naoum V, Kyriopoulos D, Charonis A, Athanasakis K, Kyriopoulos J. ***"The Pareto Principle in Healthcare Service in Greece"***". Value in Health, 2016, 19 (7), A618
51. Tsiantou V, Karampli E, Zavras D, Skroumpelos A, Athanasakis K, Mylona K, Pavi E, Kyriopoulos J. ***"Delays In Breast Cancer Diagnosis And Initiation of Treatment: Implementing The Pathways To Treatment Model In The Greek Setting"***". Value in Health, 2016 19 (7), A623
52. Tsakalogiannis C, Karampli E, Athanasakis K, Kyriopoulos J. ***"Stakeholders Views On The Role Of HTA And RSAs In Pharmaceutical Policy In Greece"***". Value in Health. 2016 19 (7), A466
53. Athanasakis K, Tarantilis F, Skroumpelos A, Kyriopoulos J. ***"Cost-Effectiveness Analysis of Tocilizumab Subcutaneous combotherapy First Line For The Management of Rheumatoid Arthritis In Greece"***". Value in Health, 2016, 19 (7), A538
54. Kyriopoulos I, Petropoulou A, Naoum V, Oikonomou N, Athanasakis K, Kyriopoulos J. ***"Cost-Sharing In Healthcare: An Approach For Pharmaceutical Care In Greece"***". Value in Health, 2016, 19 (7), A458

55. Karampli E, Tsiantou V, Skroumpelos A, Mylona K, Athanasakis K, Zavras D, Pavi E, Kyriopoulos J. ***“The Patient Journey After A Diagnosis of Early/Locally Advanced Breast CA In Greece And Choice of Provider”***. Value in Health, 2016 19 (7), A625
56. Athanasakis K, Tarantilis F, Naoum P, Kyriopoulos J. ***“A Budget Impact Analysis of Alternative Treatment Options for Colorectal Cancer in Greece”***. Value in Health, 2016, 19 (7), A718
57. Charonis A, Balasopoulos T, Naoum P, Mavrikou M, Karokis A, Athanasakis K, Pavi E, Kyriopoulos J. ***“Investigating The Perceptions Of The Greek Population Towards The Efficacy And Safety Of Generic Drugs”***. Value in Health, 2016, 19 (7), A484
58. Athanasakis K, Boubouchairopoulou N, Kyriopoulos I, Tsoulas C, Tzanakis B, Kyriopoulos J. ***“Cost-Effectiveness Analysis Of Sofosbuvir For Genotype 2 Hepatitis C In Greece”***. Value in Health, 2016, 19 (7), A415
59. Naoum P, Mavrikou M, Charonis A, Balasopoulos T, Kyriopoulos I, Karokis A, Athanasakis K, Pavi E, Kyriopoulos J. ***“The Utilization Of Selected Screening Tests In Greece: A Descriptive Analysis”***. Value in Health, 2016, 19 (7), A476
60. Athanasakis K, Boubouchairopoulou N, Kyriopoulos I, Tsoulas C, Tzanakis B, Kyriopoulos J. ***“Cost-Effectiveness Analysis Of Highly Innovative Treatments For Hepatitis C: The Case Of Ledipasvir/Sofosbuvir In A Greek Healthcare Setting”***. Value in Health, 2016, 19 (7), A413-A414
61. Chounta A, Pliarchopoulou F, Chatzimichael K, Broutzos E, Filippiadis D, Panayiotides I, Kyriazopoulou E, Athanasakis K. ***“A cost of illness analysis of HCC in a setting of severe financial constraints”***. Hepatology International 2016;10 (SUPPL. 1): S333
62. Kasiakogias A, Tsioufis C, Athanasakis K, Andrikou E, Konstantinidis D, et al ***“Real-world medication compliance in a sample of patients receiving antihypertensive treatment in Greece”***. Journal of Hypertension, 2016, 34, e72
63. Athanasakis, K., Boubouchairopoulou, N., Tarantilis, F., Tsiantou, V., Kontodimas, S., Kyriopoulos, J. ***“Cost-Effectiveness Analysis of Topical Filed Treatment***

- Therapies for The Treatment of Actinic Keratosis In Greece*". Value in Health, 2015, 18(7), A422.
64. Athanasakis, K., Kyriopoulos, I., Karokis, A., Manias, N. G., Kyriopoulos, J., Ollandezos, M. ***"In Greece, During 2009-2014, Public Pharmaceutical Expenditure Undoubtedly Fell; But On Whose Backs?"***. Value in Health, 2015, 18(7), A532.
65. Athanasakis, K., Boubouchairopoulou, N., Naoum, P., Akalestos, T., Skroumpelos, A., Kyriopoulos, J. ***"Budget Impact Analysis Of N-Terminal Pro-B-Type Natriuretic Peptide Testing For The Diagnosis And Prognosis Of Heart Failure In Greece"***. Value in Health, 18(7), 2015, A348-A349.
66. Petrakis, I., Kyriopoulos, J., Athanasakis, K. ***"Reforming The Reformed-Hospital Pharmaceutical Expenditure In Greece Over The Crisis Era; Looking At What Has Been Achieved When Planning Ahead"***. Value in Health, 2015, 18(7), A531.
67. Charonis, A., Kyriopoulos, I., Athanasakis, K., Pavi, E., Kyriopoulos, J. ***"The Intertemporal Changes Of Health Services Utilization During The Last Decade: The Case Of Austerity Inflicted On Greece"***. Value in Health, 2015, 18(7), A525-A526.
68. Athanasakis, K., Zhuo, J., Chen, J., Boubouchairopoulou, N., Tarantilis, F., Papageorgiou, M., Kyriopoulos, J. ***"Cost-Effectiveness of Sitagliptin Compared to Sulphonylurea as an Add-on to Metformin in the Treatment of Type 2 Diabetes in Greece"***. Value in Health, 2015, 18(7), A608.
69. Charonis, A., Spanakis, M., Kyriopoulos, I., Zavras, D., Athanasakis, K., Pavi, E., Kyriopoulos, J. ***"The Relationship Between Socioeconomic Characteristics And Self-Rated Health In Greece"***. Value in Health, 2015, 18(7), A527.
70. Athanasakis K., Papageorgiou L., Tsiantou V., Petropoulou A., Boubouchairopoulou N., Tarantilis F., Kyriopoulos, J. ***"Rituximab SC Vs Rituximab IV for non-Hodgkin's Lymphomas (NHLs): an Economic Evaluation for the Greek Healthcare System"***. Value in Health, 2015, 18(7), A444.
71. Athanasakis, K., Tarantilis, F., Skroumpelos, A., Kyriopoulos, J. ***"Cost-Effectiveness Analysis of Tocilizumab Subcutaneous As First Line Biologic Monotherapy for Rheumatoid Arthritis Management In Greece"***. Value in Health, 2015, 18(7), A671.

72. Kyriopoulos, D., Charonis, A., Athanasakis, K., Pavi, E., Kyriopoulos J. ***“Trends In Self-Rated Health Status Among Adults In Greece (2002-2015)”***. Value in Health, 2015, 18(7), A563
73. Tsiantou, V., Athanasakis, K., Theodoropoulou, F., Kyriopoulos, J. ***“Patients’ and Health Professionals’ Preferences Regarding Intravenous Vs Subcutaneous Drug Administration: A Literature Review”***. Value in Health, 2015, 18(7), A742.
74. Manias, N. G., Kyriopoulos, I., Ollandezos, M., Athanasakis, K., Kyriopoulos, J. ***“The Impact of the increasing Penetration of on-Patent Medicines on the Greek Pharmaceutical Market”***. Value in Health, 2015, 18(7), A516-A517
75. Bertias G, Karampli E, Sidiropoulos P, Drosos A, Sakkas L, Garyfallos A, Tzioufas A, Vassilopoulos D, Sfrikakis P, Athanasakis K, Perna A, Psomali D, Kyriopoulos J, Boumpas D. ***“Clinical and financial burden of sle in greece: a nation-wide, multi-centre study”***. Annals of Rheumatic Diseases 2015;74(Suppl2): 571
76. Siakou A, Athanasakis K: ***“Exploring the Impact of health-care cost sharing mechanisms in health service users for all the 27 member countries of the EU”*** Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P29
77. Tsifetaki N, Migkos M, Papagoras C, Voulgari P, Athanasakis K, Drosos A. ***“Counting Costs Under Severe Financial Constraints: A Cost of Illness Analysis of Spondyloarthropathies in Greece”*** Annals of Rheumatic Diseases 2015;74:743 doi:10.1136/annrheumdis-2015-eular.3370
78. Papafaklis M, Igoumenidis M, Athanasakis K, Andreou I, Michalis L. ***“Projected Cost of Computed Tomography-Derived Fractional Flow Reserve in Suspected Coronary Artery Disease: Effect of Enhanced Image Quality and Technology Refinements”*** JACC, 2015, 65(10S) A1104
79. Karachaliou, F. Athanasakis, K. Tsendidis, C. Kitra, M. Simatos, G. Michalakos, S. Karavanaki, K. ***“Insulin pump therapy in childhood diabetes - cost implications”***. Pediatric Diabetes. 15 (Supplement 19):100, September 2014.
80. Athanasakis K, Makras P, Boubouchairopoulou N, Rizou S, Kyriopoulos J, Lyritis G. ***“Estimating the Cost-Effective Intervention Thresholds for Osteoporotic Fractures Based on Frax® in the Greek Setting”*** Value in Health, 2014, 17 (7), A379

81. Athanasakis K, N Boubouchairopoulou N, Retsa MP, Maiese EM, Kyriopoulos J
“Cost-Effectiveness Analysis of Raltegravir in HIV-Infected Treatment Naive Patients in Greece” Value in Health, 2014, 17 (7), A675
82. Boubouchairopoulou K, Athanasakis K, Chini M, Mangafas N, Lazanas M, Kyriopoulos J
“Cost Estimation of HIV Infection in Greece: Data from an Infectious Diseases Unit” Value in Health, 2014, 17 (7), A671
83. Athanasakis K, Boubouchairopoulou N, Alexiou V, Baroutsou B, Kyriopoulos J
“Clinical Trial Activity in Greece From 2010 To 2012: Still Missing the Opportunities?” Value in Health, 2014, 17 (7), A433
84. Boubouchairopoulou N, Karpettas N, Athanasakis K, Kollias A, Protogerou AD, Achimastos A, Stergiou GS
“Cost Estimation Of Home Blood Pressure Monitoring Versus Combined Office And Ambulatory Measurements In Hypertension Management” Value in Health, 2014, 17 (7), A481
85. Tsiantou V, Mylona K, Karampli E, Boubouchairopoulou N, Kyriopoulos II, Athanasakis K, Kyriopoulos J.
“Access To Orphan Drugs In Greece During Economic Crisis” Value in Health, 2014, 17 (7), A541
86. Tsiantou V, Zavras D, Karampli E, Athanasakis K, Pavi E, Kyriopoulos J.
“Physicians Estimation Regarding The Impact Of Recession on Patient Adherence To Treatment In Diabetes Type 2 In Greece” Value in Health, 2014, 17 (7), A357
87. Athanasakis K, Karampli E, Psomali D, Perna A, Kyriopoulos J
“The Cost of Active Systemic Lupus Erythematosus in Greece Results From the Lycos Study” Value in Health, 2014, 17 (7), A529
88. Tsiantou V, Zavras D, Karampli E, Athanasakis K, Pavi E, Kyriopoulos J.
“Is the rule of halves applicable in Diabetes Type 2? Evidence from Greece” Value in Health, 2014, 17 (7), A357
89. Athanasakis K, Karampli E, Ollandezos M, Igoumenidis M, Karabela P, Kyriopoulos J.
“Belimumab for the Treatment of Systemic Lupus Erythematosus (SLE) In Greece: A Cost-Effectiveness and Cost-Utility Analysis” Value in Health, 2014, 17 (7), A532-A533

90. Parissis J, Athanasakis K, Farmakis D, et al ***“ Heart failure hospitalization cost in a Greek public tertiary hospital”*** European Journal of Heart Failure, 2014, 16, 346-347
91. Karachaliou, F., Athanasakis, K., Tsendidis, C., Kitra, M., Michalacos, S., Karavanaki, K. ***“Predictors of Direct Costs of Pediatric Diabetes in Greece”***. Hormone Research in Paediatrics 2014;82(suppl 1):I-IV
92. Athanasakis K, Arzoumanidou D, Petrakis I, Karampli E, Retsa P, Theodoropoulou T, Kyriopoulos J ***“A Cost-Of-Illness Analysis of Hepatitis C in Greece”***. Value in Health, 2013, 16(7): A496
93. Tarantilis F, Athanasakis K. ***“Estimates of Price and Income Elasticity in Greece: Greek Debt Crisis Transforming Cigarettes into a Luxury Good”***. Value in Health, 2013, 16(7): A377
94. Athanasakis K, Konstantopoulou T, Tarantilis F, Tsalapati K, Vritzali E, Kyriopoulos J ***“Cost-Utility Analysis of Tocilizumab in Combination with Methotrexate Versus Standard of Care for the Treatment of Rheumatoid Arthritis in Greece”***. Value in Health, 2013, 16(7): A565
95. Tsalapati K, Athanasakis K, Pavi E, Kyriopoulos J ***“The Impact of Smoking on Hospital Costs in Times of Crisis; An Additional Burden to the Vulnerable Greek Health Care System”***. Value in Health, 2013, 16(7): A369
96. Athanasakis K, Konstantopoulou T, Tarantilis F, Tsalapati K, Vritzali E, Kyriopoulos J ***“Cost-Utility Analysis of Tocilizumab Monotherapy Versus Standard of Care for the Treatment of Rheumatoid Arthritis in Greece”***. Value in Health, 2013, 16(7): A565
97. Athanasakis K, Karampli E, Retsa P, Theodoropoulou T, Kyriopoulos J ***“Cost Effectiveness Analysis of Boceprevir (BOC) Added to Pegifn/Ribavirin (P/R) Versus Pegifn/Ribavirin (Current Standard of Care) for the Treatment of Patients with Genotype 1 Chronic Hepatitis C in Greece”***. Value in Health, 2013, 16(7): A352
98. Athanasakis K, Arzoumanidou D, Karampli E, Armelidou E, Giovas P, Petrikkou E, Kyriopoulos J ***“Cost-Effectiveness of Apixaban Versus Standard of Care for the Prevention of Stroke: An Analysis of Patients with Atrial Fibrillation in Greece”***. Value in Health, 2013, 16(7): A524-525

99. Athanasakis K, Arzoumanidou D, Karampli E, Armelidou E, Giovas P, Petrikkou E, Kyriopoulos J ***“Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis of Patients with Atrial Fibrillation in Greece”***. Value in Health, 2013, 16(7): A525
100. Athanasakis K, Petrakis I, Kyriopoulos J ***“Investigating the Value of Abatacept IV in the Treatment of Rheumatoid Arthritis: A Systematic Review of Cost-Effectiveness Studies”*** Value in Health, 2013, 16(7): A563
101. Athanasakis K, Petrakis I, Tsoulas C, Vatopoulos A ***“The economic burden of initial empiric antibiotic failure on health care resource utilization for hospitalized patients with complicated intra-abdominal infections (CIAIs) in Greece”*** Value in Health, 2012, 15(7): A391
102. Athanasakis K, Petrakis I, Kyriopoulos J. ***“Cost-effectiveness of posaconazole compared to fluconazole/itraconazole for the prevention of invasive fungal infections in neutropenic patients”*** Value in Health, 2012, 15(7): A393
103. Insinga RP, Konstantopoulou T, Athanasakis K, Argyris G ***“Budget impact of using sugammadex for the routine reversal of neuromuscular blockade in a Greek health care setting”*** Value in Health, 2012, 15(7): A440
104. Athanasakis K, Petrakis I, Karabela P, Vitsou E, Pimenidou A, Kyriopoulos J. ***“A cost-effectiveness analysis of parecoxib in the management of post-operative pain in the Greek health care setting”*** Value in Health, 2012, 15(7): A512
105. Athanasakis K, Karampli E, Hollandezos M, Papagiannopoulou V, Badamgarav E, Intorcia M, Kyriopoulos J. ***“The Economic Burden of Post-Menopausal Osteoporosis and Related Fractures in Greece”*** Value in Health, 2011, 14(7): A305
106. Athanasakis K, Karampli E, Hollandezos M, Papagiannopoulou V, Badamgarav E, Intorcia M, Kyriopoulos J. ***“A Cost-Effectiveness Analysis of Denosumab for the Treatment of Post-Menopausal Osteoporosis in Greece”*** Value in Health, 2011, 14(7): A308
107. Athanasakis K, Igoumenidis M, Karampli E, Vitsou E, Kyriopoulos J. ***“A Cost-Effectiveness Analysis of Varenicline Versus Bupropion and Nicotine Replacement Therapy in Greece”*** Value in Health, 2011, 14(7): A493

108. Athanasakis K, Golna C, Kyriopoulos J. ***“Cost-Effectiveness Analysis of Trastuzumab + Docetaxel Versus Docetaxel Alone in the Treatment of HER2+ Metastatic Breast Cancer”*** Value in Health, 2011, 14(7): A449
109. Athanasakis K, Zavras D, Kyriopoulos J. ***“Socioeconomic Determinants of Smoking Status in Greece”*** Value in Health, 2011, 14(7): A500
110. Athanasakis K, Detsis M, Baroutsou B, Kyriopoulos J. ***“Clinical Trial Activity in Greece: Opportunities Missed, Soon to be Forgone?”*** Value in Health, 2011, 14(7): A352
111. Athanasakis K, Sideris M, Zacharis M, Zouvelou V, Evdokimidis I, Kyriopoulos J. ***“A Cost-of-Illness Analysis Of Amyotrophic Lateral Sclerosis In Greece”*** Value in Health, 2011, 14(7): A320
112. Athanasakis K, Glava V, Zacharis M, Zouvelou V, Evdokimidis I, Kyriopoulos J. ***“A Cost-of-Illness Analysis of Myasthenia Gravis in Greece”*** Value in Health, 2011, 14(7): A321
113. Tsiantou V, Athanasakis K, Pavi E, Kyriopoulos J. ***“In Search of Reform for the Greek Health Care System: Depicting the Key Opinion Leaders' Views”*** Value in Health, 2011, 14(7): A359
114. Athanasakis K, Zavras D, Kyriopoulos J. ***“Factors influencing the decision to be vaccinated against H1N1 in Greece”*** Value in Health, 2010, 13(7): A443
115. Athanasakis K, Karampli E, Kyriopoulos J. ***“Physicians' views of the relative importance of selected medical innovations on the Greek population health status”*** Value in Health, 2010, 13(7): A424
116. Tsiantou V, Skroumpelos A, Mylona K, Athanasakis K, Konstantinopoulos O, Kyriopoulos J. ***“Physicians views on biomedical technology in Greece”*** Value in Health, 2010, 13(7): A407
117. Maniadakis N, Athanasakis K, Fragoulakis V, Tsiantou V, Kyriopoulos J. ***“Economic evaluation of ranibizumab in the treatment of age-related macular degeneration in Greece”*** Value in Health, 2010, 13(7): A399
118. Maniadakis N, Fragoulakis V, Athanasakis K, Kyriopoulos J. ***“Economic evaluation of dronedarone in treatment of atrial fibrillation in Greece”*** Value in Health , 2010, 13(7): A357

119. Athanasakis K, Karampli E, Ollandezos M, Kyriopoulos J. ***“Estimating the cost of atrial fibrillation in Greece”*** Value in Health, 2010, 13(7): A350
120. Souliotis K, Athanasakis K, Palaka E, Kyriopoulos II, Golna C, Kyriopoulos J. ***“Inequalities in geographical access to oncology services in greece and their impact on patients and carers”*** Value in Health, 2010, 13(7): A279
121. Athanasakis K, Karampli E, Hollandezos M, Kyriopoulos J. ***“Atrial Fibrillation management patterns in Greece”*** Hellenic Journal of Cardiology, 2010, 51 Supplement A: 30
122. Tsalta D, Athanasakis K, Konstantopoulou A, Kyriopoulos J, Papadogiannis D. ***“Estimating the cost of treatment in a specialized National Health System hypertension centre in Greece”*** Journal of Hypertension, 2010, 28, e-Supplement A: e398-e399
123. Athanasakis K, Souliotis K, Kyriopoulos J. ***“Cross-regional flows of cancer patients in Greece: urbanization of cancer treatment”*** Value in Health, 2009, 12(6): A286
124. Athanasakis K, Detsis M, Kyriopoulos J. ***“Greek NHS capacity constraints regarding IV treatment for rheumatoid arthritis patients”*** Value in Health, 2009, 12(6): A451
125. Geitona M, Kousoulakou C, Hollandezos M, Athanasakis K, Papanikolaou S, Kyriopoulos J. ***“Direct cost of treating patients with schizophrenia in Greece: real-world data from the electronic schizophrenia treatment adherence registry (e-star)”*** Value in Health, 2008, 11(6):A345
126. Souliotis K, Athanasakis K, Golna C, Papadopoulou C, Kyriopoulos J. ***“Availability and spatial distribution of oncology specific resources in Greece”*** Value in Health 2008, 11(6):A491
127. Athanasakis K, Hollandezos M, Angeli A, Gregoriou A, Geitona M, Kyriopoulos J. ***“Estimating the direct cost of type II diabetes in Greece”*** Value in Health, 2008, 11(6):A505
128. Karampli E, Hollandezos M, Kousoulakou C, Tsiantou V, Athanasakis K, Kyriopoulos J. ***“Pharmaceutical expenditure in greece 1980-2006”*** Value in Health, 2008, 11(6):A372

129. Kalampokas T, Maravelakis P, Gregory S, Athanasakis K, Geitona M, Kyriopoulos J. ***“Willingness to pay of young Greek women for the new antiHPV vaccine”*** Value in Health, 2007, 10(6):A379
130. Kyriopoulos J, Athanasakis K, Zavras A, Angeli A, Geitona M. ***“Cost-effectiveness of hypertension treatment in Greece-the ECON-APROS study”*** Value in Health, 2007, 10(6):A411
131. Geitona M, Athanasakis K, Angeli A, Hatzakis A, Kyriopoulos J. ***“The impact of lowering systolic blood pressure on the QoL of hypertensive patients in Greece: the ECON-APROS study”*** Value in Health, 2007, 10(6):A432